As for possible nanotechnology-driven delivery, in vitro and in vivo studies were performed by Nikpoor and colleagues, who proposed two liposome formulations, one polyethylene glycol (PEG)ylated and the second non-PEGylated, containing anti-CTLA-4 blocking mAb in a C-26 colon cancer model [59]. Here, CTLA4 is linked to colonic neoplasm.